235 related articles for article (PubMed ID: 25715778)
21. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of serum ferritin as a tumor marker for canine histiocytic sarcoma.
Friedrichs KR; Thomas C; Plier M; Andrews GA; Chavey PS; Young KM
J Vet Intern Med; 2010; 24(4):904-11. PubMed ID: 20561186
[TBL] [Abstract][Full Text] [Related]
23. Establishment and characterisation of cell lines and xenograft mouse models of canine systemic histiocytosis and disseminated histiocytic sarcoma.
Hirabayashi M; Chambers JK; Kishimoto TE; Nguyen SV; Ishikawa Y; Rimpo K; Nakayama H; Uchida K
Vet Comp Oncol; 2022 Jun; 20(2):465-475. PubMed ID: 34907644
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2014 Jan; 199(1):103-9. PubMed ID: 24332606
[TBL] [Abstract][Full Text] [Related]
25. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Skorupski KA; Rodriguez CO; Krick EL; Clifford CA; Ward R; Kent MS
Vet Comp Oncol; 2009 Jun; 7(2):139-44. PubMed ID: 19453368
[TBL] [Abstract][Full Text] [Related]
26. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.
Laursen MB; Falgreen S; Bødker JS; Schmitz A; Kjeldsen MK; Sørensen S; Madsen J; El-Galaly TC; Bøgsted M; Dybkær K; Johnsen HE;
Exp Hematol; 2014 Nov; 42(11):927-38. PubMed ID: 25072621
[TBL] [Abstract][Full Text] [Related]
27. Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.
Januchowski R; Wojtowicz K; Andrzejewska M; Zabel M
Biomed Pharmacother; 2014 Feb; 68(1):111-7. PubMed ID: 24140176
[TBL] [Abstract][Full Text] [Related]
28. Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.
Chen W; Liu I; Tomiyasu H; Lee J; Cheng C; Liao AT; Liu B; Liu C; Lin C
Vet J; 2019 Dec; 254():105398. PubMed ID: 31836165
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Li WW; Takahashi N; Jhanwar S; Cordon-Cardo C; Elisseyeff Y; Jimeno J; Faircloth G; Bertino JR
Clin Cancer Res; 2001 Sep; 7(9):2908-11. PubMed ID: 11555609
[TBL] [Abstract][Full Text] [Related]
30. Serum level of apoptosis inhibitor of macrophage in dogs with histiocytic sarcoma and its association with the disease.
Uchida M; Matsumiya Y; Tsuboi M; Uchida K; Nakagawa T; Fujii W; Kobayashi T; Tsujimoto H; Ohmi A; Tomiyasu H; Motegi T; Maeda S; Momoi Y; Yonezawa T
Vet Comp Oncol; 2023 Sep; 21(3):391-400. PubMed ID: 37088561
[TBL] [Abstract][Full Text] [Related]
31. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
[TBL] [Abstract][Full Text] [Related]
32. Clinical prognostic factors in canine histiocytic sarcoma.
Dervisis NG; Kiupel M; Qin Q; Cesario L
Vet Comp Oncol; 2017 Dec; 15(4):1171-1180. PubMed ID: 27334037
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
34. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
35. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Thaiwong T; Sirivisoot S; Takada M; Yuzbasiyan-Gurkan V; Kiupel M
Vet Comp Oncol; 2018 Jun; 16(2):220-228. PubMed ID: 28929581
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma.
Prouteau A; Denis JA; De Fornel P; Cadieu E; Derrien T; Kergal C; Botherel N; Ulvé R; Rault M; Bouzidi A; François R; Dorso L; Lespagnol A; Devauchelle P; Abadie J; André C; Hédan B
Sci Rep; 2021 Jan; 11(1):877. PubMed ID: 33441840
[TBL] [Abstract][Full Text] [Related]
37. The intratumor heterogeneity of TP53 gene mutations in canine histiocytic sarcoma.
Asada H; Ichii O; Tomiyasu H; Uchida K; Chambers JK; Goto-Koshino Y; Ohno K; Kon Y; Tsujimoto H
J Vet Med Sci; 2019 Mar; 81(3):353-356. PubMed ID: 30662044
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
39. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases expression in spontaneous canine histiocytic sarcomas and its xenograft model.
Fayyad A; Lapp S; Risha E; Pfankuche VM; Rohn K; Barthel Y; Schaudien D; Baumgärtner W; Puff C
Vet Immunol Immunopathol; 2018 Apr; 198():54-64. PubMed ID: 29571518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]